{
    "nctId": "NCT02483767",
    "briefTitle": "Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer",
    "officialTitle": "Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 98,
    "primaryOutcomeMeasure": "ovarian failure",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patients signed the written informed consent.\n* Histologically proven stage I, II, or III breast cancer\n* Must be candidates for adjuvant or neoadjuvant chemotherapy,\n* Must be premenopausal.\n* Trastuzumab is permitted in patients with human epidermal growth factor receptor 2 (HER2) overexpressing tumors.\n\nExclusion Criteria:\n\n* The patients were previous chemotherapy;\n* Evidence of distant metastases;\n* Other malignancies in the previous 5 years.\n* The patients were using GnRHa, progesterone, stimulate ovulation drugs, oral contraceptives, aromatase inhibitors, intrauterine device with hormone, subcutaneous preparations contraceptive drugs such as hormone drugs and instruments during 3 month preceding the start of chemotherapy.\n* Pregnancy or lactation.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}